Rondecabtagene autoleucel (ronde-cel, LYL314)

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotech founded in 2018 with a mission to fully realize the curative potential of cell therapy for cancer. The company is advancing a pipeline of next-generation CAR-T therapies, featuring a pivotal-stage dual-targeting candidate for large B-cell lymphoma and a Phase 1 program for metastatic colorectal cancer. Its strategy is built on deep T-cell biology expertise, proprietary manufacturing, and vertical integration to improve outcomes in hematologic malignancies and pioneer breakthroughs in solid tumors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotech founded in 2018 with a mission to fully realize the curative potential of cell therapy for cancer. The company is advancing a pipeline of next-generation CAR-T therapies, featuring a pivotal-stage dual-targeting candidate for large B-cell lymphoma and a Phase 1 program for metastatic colorectal cancer. Its strategy is built on deep T-cell biology expertise, proprietary manufacturing, and vertical integration to improve outcomes in hematologic malignancies and pioneer breakthroughs in solid tumors.

Therapeutic Areas